Aducanumab (BIIB037) showed significant time and dose dependent reduction of beta amyloid in the brain of AD patients

At the 33rd Annual J.P.Morgan Healthcare Conference in San Francisco, Biogen Idec reported on the top line interim results from the current Phase 1b trial of Aducanumab (BIIB037) in prodromal or mild Alzheimer’s disease patients. BIIB037 significantly reduced beta amyloid in the brain of AD patients in a time and dose dependent manner and showed an acceptable safety profile to date. In addition, in exploratory analyses, BIIB037 showed a statistically significant impact on cognition at one year. Biogen Idec announced that the data from the Phase 1b trial will be presented at the AD/PD meeting in Nice, France, March 18-22, 2015.